Gary Clark: Unfiltered

A $3.4M contract for a custom rig reveals a strategic shift in Canada's energy sector, where bespoke technology is the new competitive advantage.

An animation streaming firm is building a massive AI supercomputer in Malaysia. Is it a visionary pivot or a high-stakes bet beyond its expertise?

A new contract for its explainable AI in a pivotal Phase 3 trial shows NetraMark is helping Big Pharma de-risk its most expensive R&D phase.

As quantum threats loom, SEALSQ's strategic entry into medical chips with post-quantum cryptography could redefine data security and the industry's supply chain.

Scienjoy's launch of AI Vista Live! in Dubai is more than a tech debut; it's a strategic play in a $200B digital human market. Here's why it matters.

Massimo Group's new HVAC-equipped electric utility vehicles are more than a comfort upgrade; they represent a strategic bid for the lucrative commercial fleet market.

Nasdaq-listed Society Pass is ditching its e-commerce roots for the AI gold rush. Is this a savvy M&A masterstroke or a risky gamble in a capital-heavy arena?

Polyrizon's novel hydrogel shows it can stick to nasal tissue longer without slowing drug delivery, a key innovation in the fight against opioid overdose.

Impressive drill results from Lapon Canyon are turning heads, but the discovery of monzonite-hosted gold suggests a much larger story is unfolding.

As lithium fire risks escalate, a small-cap firm's live EV burn demo in Houston draws industry giants, signaling a pivotal moment for safety tech.

Beyond its first-ever dividend, Covalon's true story is one of clinical innovation driving record sales, navigating market shifts, and funding global growth.

Promising interim data for a Parkinson's vaccine sends AC Immune's stock soaring, signaling a potential paradigm shift from symptom management to disease modification.

With a 2026 decision date set, Lifezone Metals is de-risking a world-class nickel project in Tanzania, promising to shake up the global battery supply chain.

Apollo Silver plans to revive a massive California silver deposit, aligning with US strategic goals. Can it overcome technical and environmental hurdles?

Bristol Myers Squibb's Opdivo gets FDA priority review, backed by landmark data suggesting it could unseat a key competitor as the new gold standard.

Rezolute's stock plummets after its lead drug fails a key trial, raising questions about its future and highlighting the brutal realities of biotech.

As EVgo nears breakeven, it brings in a seasoned financial architect from the energy sector to steer its capital-intensive buildout toward profitability.

RecycLiCo's new R&D hub is more than just a building; it's a strategic play in the high-stakes game of critical mineral independence.

A Belgian med-tech firm is replacing a centuries-old procedure with an implantable pump, targeting a growing multi-billion dollar liver disease market.

Stewart Information Services is raising millions via a stock offering. We analyze the strategy, the market signals, and the impact on shareholder value.